The BDCP clinical study is for type 1 diabetes patients, 18 years or older, to evaluate the safety of LY3209590 in patients being treated with multiple daily injection therapy.
Learn More
The SUNRISE study is a prospective, multi-center, double-blind, randomized, placebo-controlled trial in subjects aged 18.0 to <41.0 years diagnosed with T1D within 5 years.
Learn More
The purpose of the 321 trial is to evaluate the safety of the Advanced Hybrid Closed Loop system (AHCL) in type 1 diabetes in pediatric subjects age 7 – 13 in a home setting. The main objective in conducting this research is to collect data from patients who use the AHCL system at home, at work, at school and everywhere else.
Learn More
The Protect study is to determine whether teplizumab slows the loss of β cells and preserves β cell function in children and adolescent 8-17 years old who have been diagnosed with T1D in the previous 6 weeks.
Learn More
(ITSB) The reason for this study is to compare a ultra-rapid lispro to insulin lispro (Humalog) in children and adolescents with type 1 diabetes (T1D).
Learn More
A 52-week study that compares the efficacy of Relamorelin with that of placebo in participants with diabetic gastroparesis with respect to the core signs and symptoms of diabetic gastroparesis(RLM-MD).
Learn More
Seeking Type 1 pediatric subjects who are on multiple daily injections interested in using a new Closed Loop pump system (Med 304).
Learn More
Seeking pediatric Type 1 subjects to assess accuracy and reliability of a new-to-market flash glucose monitoring system (Libre Flash).
Learn More
Click Here